After 7-day treatment, tumors from vehicle-treated mice reached ~ 1475 mm3 in size, whereas those from AZD5363 -treated mice only reached ~ 188 mm3, which was comparable with that of the tumor size at the start of treatment (~ 224 mm3) (p = 0.59) (Fig. 6d), indicating that treatment with AZD5363 prevents estrogen-enhanced Brca1-deficient tumor progression. The gene discussed is BRCA1; the disease is neoplasm.